Open an account

Glaukos

GKOS · NYSE

$173.43+$6.47 (+3.88%)TodayMarket closed ·
Prev close $166.96

About GKOS

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in Aliso Viejo, California and currently employs 1,094 full-time employees. The company went IPO on 2015-06-25. The firm is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

Employees
1,094
Headquarters
Aliso Viejo, California
Listed
Jun 25, 2015
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
glaukos.com

GKOS key statistics

Market cap
9.85B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
991.19K
Volume
613.92K
Open price
$168.30
High today
$176.07
Low today
$168.00
52 Week high
$191.62
52 Week low
$73.16

Glaukos (GKOS) at a glance

As of Oct 20, 2026, Glaukos (GKOS) shares are priced at $173.43, giving the company a market cap of 9.85B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $168.00 and $176.07. The current price is 3.2% above the day's low and 1.5% below its high.

Volume so far is 613.92K shares, below the average of 991.19K shares a day.

Over the past year Glaukos has ranged from $73.16 to $191.62, and now sits 85% of the way up that range.

Glaukos met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.14 per share against an estimate of -$0.2149.

GKOS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 33.5% on average.

  1. Q3 FY24: reported -$0.28 per share against an estimate of -$0.4872
  2. Q4 FY24: reported -$0.40 per share against an estimate of -$0.3911
  3. Q1 FY25: reported -$0.22 per share against an estimate of -$0.3546
  4. Q2 FY25: reported -$0.24 per share against an estimate of -$0.2699
  5. Q3 FY25: reported -$0.16 per share against an estimate of -$0.2629
  6. Q4 FY25: reported -$0.28 per share against an estimate of -$0.2001
  7. Q1 FY26: reported -$0.18 per share against an estimate of -$0.2782
  8. Q2 FY26: reported -$0.14 per share against an estimate of -$0.2149

GKOS news

  • Vandana Singh

    Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy

  • Press releaseBusiness Wire

    Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery

  • Vandana Singh

    Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal

  • Press releaseBusiness Wire

    Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases

  • Press releaseBusiness Wire

    Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus

  • Press releaseBusiness Wire

    Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28

  • Press releaseBusiness Wire

    Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus

  • Press releaseBusiness Wire

    Glaukos Announces Participation in Wells Fargo Healthcare Conference

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.